About Human Combination Vaccines A vaccine is made up of inactive, partially killed or dead viruses, to stimulate the immune system against the pathogenic virus and produce antibodies against it. Vaccines are injected or orally administered. Animal vaccines provide immunity to the animal body against pathogens. They are composed of attenuated or dead virus strains and can be administered via the intramuscular, intradermal, or oral route. Similarly, human vaccines are composed of inactivated or live attenuated virus particles and provide immunity to the human body against different pathogens and can be administered via the intramuscular, intradermal, oral, and subcutaneous route. The modern human vaccines are mostly composed of inactivated virus strains. Technavio’s analysts forecast the global Human Combination Vaccines market to grow at a CAGR of 8.56% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global Human Combination Vaccines market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic versions of human... Research Beam Model: Research Beam Product ID: 1625296 3500 USD New
Global Human Combination Vaccines Market 2017-2021
 
 

Global Human Combination Vaccines Market 2017-2021

  • Category : Healthcare
  • Published On : June   2017
  • Pages : 86
  • Publisher : Technavio
 
 
 
About Human Combination Vaccines
A vaccine is made up of inactive, partially killed or dead viruses, to stimulate the immune system against the pathogenic virus and produce antibodies against it. Vaccines are injected or orally administered. Animal vaccines provide immunity to the animal body against pathogens. They are composed of attenuated or dead virus strains and can be administered via the intramuscular, intradermal, or oral route. Similarly, human vaccines are composed of inactivated or live attenuated virus particles and provide immunity to the human body against different pathogens and can be administered via the intramuscular, intradermal, oral, and subcutaneous route. The modern human vaccines are mostly composed of inactivated virus strains.

Technavio’s analysts forecast the global Human Combination Vaccines market to grow at a CAGR of 8.56% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global Human Combination Vaccines market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic versions of human combination vaccines.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Human Combination Vaccines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• GlaxoSmithKline
• Merck
• Sanofi
Other prominent vendors
• Daiichi Sankyo
• Serum Institute of India
• Takeda Pharmaceuticals
Market driver
• Rise in cases of infectious diseases
• For a full, detailed list, view our report

Market challenge
• Requirement of cold chain logistics
• For a full, detailed list, view our report

Market trend
• Government-sponsored programs
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.




Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Human combination vaccines: An overview
• Need for development of combination vaccines
• Technical challenges faced during formulation of combination vaccines
• Strategies for developing human combination vaccines
PART 06: Key clinical trials
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by vaccine type
• Human combination inactivated vaccines
• Human combination live attenuated vaccines
PART 09: Geographical segmentation
• Human combination vaccines market in Americas
• Human combination vaccines market in EMEA
• Human combination vaccines market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Government-sponsored programs
• Growing interest toward R&D of newer vaccines
• More focus on emerging countries
• Public–private initiatives
• Threat of bioterrorism
• Improvements in healthcare infrastructure
PART 13: Vendor landscape
• Competitive landscape
PART 14: Key vendor analysis
• GlaxoSmithKline
• Merck
• Sanofi
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Advantages of human combination vaccines
Exhibit 02: Marketed human combination vaccines: Overview
Exhibit 03: Pipeline molecule based on vendors
Exhibit 04: Product pipeline
Exhibit 05: Pipeline analysis of key clinical trials
Exhibit 06: Global human combination vaccines market: Snapshot
Exhibit 07: Global human combination vaccines market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis in global human combination vaccines market
Exhibit 09: Five forces analysis
Exhibit 10: Human combination vaccines market by vaccine type
Exhibit 11: Global human combination vaccine market share by vaccine type 2016
Exhibit 12: Human combination inactivated vaccines market 2016-2021 ($ millions)
Exhibit 13: Human combination live attenuated vaccines market 2016-2021 ($ millions)
Exhibit 14: Global human combination vaccines market by geography 2016 and 2021
Exhibit 15: Global human combination vaccines market revenue by geography 2016-2021 ($ millions)
Exhibit 16: Global human combination vaccines market share by geography 2016-2021
Exhibit 17: Market scenario in Americas
Exhibit 18: Human combination vaccines market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: Human combination vaccines market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: Human combination vaccines market in APAC 2016-2021 ($ millions)
Exhibit 23: Total number of children aged 0-5 years in US (millions)
Exhibit 24: Trends in population growth in developing regions
Exhibit 25: Competitive structure analysis of global human combination vaccines market 2016
Exhibit 26: GlaxoSmithKline: Key highlights
Exhibit 27: GlaxoSmithKline: Strength assessment
Exhibit 28: GlaxoSmithKline: Strategy assessment
Exhibit 29: GlaxoSmithKline: Opportunity assessment
Exhibit 30: Merck: Key highlights
Exhibit 31: Merck: Strength assessment
Exhibit 32: Merck: Strategy assessment
Exhibit 33: Merck: Opportunity assessment
Exhibit 34: Sanofi: Key highlights
Exhibit 35: Sanofi: Strength assessment
Exhibit 36: Sanofi: Strategy assessment
Exhibit 37: Sanofi: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT